Deletion of Abcg2 Has Differential Effects on Excretion and Pharmacokinetics of Probe Substrates in Rats
暂无分享,去创建一个
B. Wong | Liyue Huang | Jonathan Roberts | Xuhai Be | Yun Ling | Lixia Jin | E. Tchaparian | A. Colletti | M. Langley
[1] J. W. Higgins,et al. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics , 2012, Drug Metabolism and Disposition.
[2] K. Maeda,et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP , 2012, British journal of pharmacology.
[3] Lixia Jin,et al. Effect of Culture Time on the Basal Expression Levels of Drug Transporters in Sandwich-Cultured Primary Rat Hepatocytes , 2011, Drug Metabolism and Disposition.
[4] Tudor I. Oprea,et al. BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.
[5] Suzanne Skolnik,et al. Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model , 2011, Drug Metabolism and Disposition.
[6] Wolfgang Löscher,et al. Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.
[7] A. S. Gross,et al. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. , 2010, Journal of pharmaceutical sciences.
[8] April Chen,et al. Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance , 2010, Drug Metabolism and Disposition.
[9] A. Kalgutkar,et al. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat. , 2009, Journal of pharmaceutical sciences.
[10] Y. Lai,et al. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion , 2009, Expert opinion on drug metabolism & toxicology.
[11] F. Pontén,et al. Correlations between RNA and protein expression profiles in 23 human cell lines , 2009, BMC Genomics.
[12] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[13] E. Kis,et al. Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. , 2009, Biological & pharmaceutical bulletin.
[14] T. Ishikawa,et al. Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations , 2009, Pharmaceutical Research.
[15] S. Bates,et al. ABCG2: a perspective. , 2009, Advanced drug delivery reviews.
[16] K. Maeda,et al. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.
[17] A. S. Gross,et al. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. , 2008, British journal of clinical pharmacology.
[18] H. Kusuhara,et al. Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.
[19] Joe Palandra,et al. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.
[20] K. Maeda,et al. SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[21] Eun-Young Kim,et al. Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population , 2007, Drug Metabolism And Disposition.
[22] T. Ishikawa,et al. Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2 , 2007, Cancer science.
[23] M. Hidalgo,et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. , 2006, Journal of the National Cancer Institute.
[24] Robert W. Robey,et al. Breast Cancer Resistance Protein , 2006 .
[25] Ya-li Liu,et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[26] T. Ishikawa,et al. Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.
[27] T. Litman,et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. , 2006, Cancer letters.
[28] J. Ware,et al. Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.
[29] J. Castle,et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[30] K. Maeda,et al. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.
[31] A. V. van Herwaarden,et al. The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.
[32] S. Bates,et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2 , 2005, Cancer Chemotherapy and Pharmacology.
[33] Y. Sugiyama,et al. Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.
[34] H. Kotani,et al. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.
[35] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[36] Y. Miki,et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.
[37] M. Vijver,et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.
[38] D. Meijer,et al. Mrp2 is essential for estradiol‐17β(β‐D ‐glucuronide)–induced cholestasis in rats , 2000 .
[39] T. Chang,et al. Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[40] M. Neville,et al. Active transport of nitrofurantoin across the mammary epithelium in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.
[41] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[42] B. Hoener,et al. Nitrofurantoin disposition , 1981, Clinical pharmacology and therapeutics.
[43] April Chen,et al. from in vitro Metabolic Intrinsic Clearance , 2009 .
[44] 雄一 杉山,et al. 医薬品添加物のBreast Cancer Resistant Protein 阻害による経口薬物吸収改善 , 2006 .
[45] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[46] E. Schuetz,et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.
[47] Y. Miki,et al. C 421 A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q 141 K Protein and Low-Level Drug Resistance 1 , 2002 .
[48] S. Bandiera,et al. EFFECT OF ANDROGEN ADMINISTRATION DURING PUBERTY ON HEPATIC CYP 2 C 11 , CYP 3 A , AND CYP 2 A 1 EXPRESSION IN ADULT FEMALE RATS , 1998 .